Serum CD121a (interleukin 1 receptor, type I): A potential novel inflammatory marker for coronary heart disease

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Liu, Zhengxia ^a   Zhang, Mengyao ^a   Wu, Jin ^a   Zhou, Ping ^a   Liu, Ying ^a   Wu, Yucheng ^a   Yang, Yujiao ^a   Lu, Xiang ^a  

^a THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 11; INTERLEUKIN 1BETA; INTERLEUKIN 8; AUTACOID; IL11 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; IL8 PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; AGE DISTRIBUTION; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENSINI SCORE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS; VERY ELDERLY; BLOOD; CASE CONTROL STUDY; CORONARY DISEASE; HEART INFARCTION; IMMUNOLOGY; MIDDLE AGED; PREDICTIVE VALUE;

ADULT; AGED; AGED, 80 AND OVER; ANGINA, STABLE; ANGINA, UNSTABLE; BIOMARKERS; CASE-CONTROL STUDIES; CORONARY DISEASE; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-11; INTERLEUKIN-1BETA; INTERLEUKIN-8; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; RECEPTORS, INTERLEUKIN-1 TYPE I;

EID: 84939157526     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131086     Document Type: Article

References (34)

1. Rothenbacher D, Muller-Scholze S, Herder C, Koenig W, Kolb H (2006) Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 26:194-199. PMID:16239601
2. Geneau R, Stuckler D, Stachenko S, McKee M, Ebrahim S, Basu S, et al. (2010) Raising the priority of preventing chronic diseases: a political process. Lancet 376:1689-1698. doi:10.1016/S0140-6736 (10) 61414-6 PMID:21074260
3. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126. PMID:9887164
4. Rothenbacher D, Kleiner A, Koenig W, Primatesta P, Breitling LP, Brenner H (2012) Relationship between inflammatory cytokines and uric acid levels with adverse cardiovascular outcomes in patients with stable coronary heart disease. PLoS One 7:e45907. doi:10.1371/journal.pone.0045907 PMID:23029307
5. Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K (2008) Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol 124:319-325. PMID:17442429
6. McCarty S, Frishman W (2014) Interleukin 1beta: a proinflammatory target for preventing atherosclerotic heart disease. Cardiol Rev 22:176-181. doi:10.1097/CRD.0000000000000022 PMID:24618930
7. Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39:1003-1018. doi:10.1016/j.immuni.2013.11.010 PMID:24332029
8. Sims JE, Smith DE (2010) The IL-1 family: regulators of immunity. Nat Rev Immunol 10:89-102. doi:10.1038/nri2691 PMID:20081871
9. Boraschi D, Tagliabue A (2013) The interleukin-1 receptor family. Semin Immunol 25:394-407. doi:10.1016/j.smim.2013.10.023 PMID:24246227
10. Chamberlain J, Francis S, Brookes Z, Shaw G, Graham D, Alp NJ, et al. (2009) Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS One 4:e5073. doi:10.1371/journal. pone.0005073 PMID:19347044
11. Alexander MR, Moehle CW, Johnson JL, Yang Z, Lee JK, Jackson CL, et al. (2012) Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest 122:70-79. doi:10.1172/JCI43713 PMID:22201681
12. Olofsson PS, Sheikine Y, Jatta K, Ghaderi M, Samnegard A, Eriksson P, et al. (2009) A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1beta:interleukin-1 receptor antagonist balance in atherosclerosis. Circ J 73:1531-1536. PMID:19574724
13. Apostolakis S, Vogiatzi K, Amanatidou V, Spandidos DA (2009) Interleukin 8 and cardiovascular disease. Cardiovasc Res 84:353-360. doi:10.1093/cvr/cvp241 PMID:19617600
14. Herder C, Baumert J, Thorand B, Martin S, Lowel H, Kolb H, et al. (2006) Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 26:2147-2152. PMID:16825597
15. Dams-Kozlowska H, Gryska K, Kwiatkowska-Borowczyk E, Izycki D, Rose-John S, Mackiewicz A (2012) A designer hyper interleukin 11 (H11) is a biologically active cytokine. BMC Biotechnol 12:8. doi:10.1186/1472-6750-12-8 PMID:22433466
16. Obana M, Miyamoto K, Murasawa S, Iwakura T, Hayama A, Yamashita T, et al. (2012) Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart. Am J Physiol Heart Circ Physiol 303:H569-577. doi:10.1152/ajpheart.00060. 2012 PMID:22707562
17. Dinarello CA (2011) A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol 41:1203-1217. doi:10.1002/eji.201141550 PMID:21523780
18. Rader DJ (2012) IL-1 and atherosclerosis: a murine twist to an evolving human story. J Clin Invest 122:27-30. doi:10.1172/JCI61163 PMID:22201674
19. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519-550. doi:10.1146/annurev. immunol. 021908.132612 PMID:19302047
20. Saxena A, Chen W, Su Y, Rai V, Uche OU, Li N, et al. (2013) IL-1 induces proinflammatory leukocyte infiltration and regulates fibroblast phenotype in the infarcted myocardium. J Immunol 191:4838-4848. doi:10.4049/jimmunol. 1300725 PMID:24078695
21. Waehre T, Yndestad A, Smith C, Haug T, Tunheim SH, Gullestad L, et al. (2004) Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 109:1966-1972. PMID:15051633
22. Beaulieu LM, Lin E, Mick E, Koupenova M, Weinberg EO, Kramer CD, et al. (2014) Interleukin 1 receptor 1 and interleukin 1beta regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans. Arterioscler Thromb Vasc Biol 34:552-564. doi:10.1161/ATVBAHA.113.302700 PMID:24458711
23. Bhaskar V, Yin J, Mirza AM, Phan D, Vanegas S, Issafras H, et al. (2011) Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. Atherosclerosis 216:313-320. doi:10.1016/j.atherosclerosis.2011. 02.026 PMID:21411094
24. Ridker PM, Thuren T, Zalewski A, Libby P (2011) Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162:597-605. doi:10.1016/j.ahj.2011.06.012 PMID:21982649
25. Davaro F, Forde SD, Garfield M, Jiang Z, Halmen K, Tamburro ND, et al. (2014) 3-Hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin)-induced 28-kDa interleukin-1beta interferes with mature IL-1beta signaling. J Biol Chem 289:16214-16222. doi:10.1074/jbc. M114.571505 PMID:24790079
26. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464:1357-1361. doi:10.1038/nature08938 PMID:20428172
27. Rajamaki K, Lappalainen J, Oorni K, Valimaki E, Matikainen S, Kovanen PT, et al. (2010) Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 5:e11765. doi:10.1371/journal.pone.0011765 PMID:20668705
28. Pang T, Wang J, Benicky J, Sanchez-Lemus E, Saavedra JM (2012) Telmisartan directly ameliorates the neuronal inflammatory response to IL-1beta partly through the JNK/c-Jun. and NADPH oxidase pathways. J Neuroinflammation 9:102. doi:10.1186/1742-2094-9-102 PMID:22642771
29. Riesenberg K, Levy R, Katz A, Galkop S, Schlaeffer F (1997) Neutrophil superoxide release and interleukin 8 in acute myocardial infarction: distinction between complicated and uncomplicated states. Eur J Clin Invest 27:398-404. PMID:9179547
30. Velasquez IM, Frumento P, Johansson K, Berglund A, De Faire U, Leander K, et al. (2014) Association of interleukin 8 with myocardial infarction: results from the Stockholm Heart Epidemiology Program. Int J Cardiol 172:173-178. doi:10.1016/j.ijcard.2013.12.170 PMID:24462138
31. Xing D, Li P, Gong K, Yang Z, Yu H, Hage FG, et al. (2012) Endothelial cells overexpressing interleukin-8 receptors reduce inflammatory and neointimal responses to arterial injury. Circulation 125:1533-1541. doi:10.1161/CIRCULATIONAHA.111.078436 PMID:22361324
32. Obana M, Maeda M, Takeda K, Hayama A, Mohri T, Yamashita T, et al. (2010) Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation 121:684-691. doi:10.1161/CIRCULATIONAHA.109.893677 PMID:20100971
33. Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S, et al. (2007) IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 117:3786-3799. PMID:17992263
34. Doz E, Noulin N, Boichot E, Guenon I, Fick L, Le Bert M, et al. (2008) Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J Immunol 180:1169-1178. PMID:18178857